Bristol-Myers Squibb (NYSE:BMY) and Evotec have advanced molecular glue candidate BMS-986506 into Phase 1 trials for clear cell renal cell carcinoma. The program marks the first clinical-stage asset ...
ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear ...
Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancerTransformative moment in ...
Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or ...
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified ...
Can you please introduce yourself and your role at LifeArc? As part of my Biochemistry degree at University of Leeds, I completed an industry placement at LifeArc. This was my first introduction to ...
A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was ...
Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...
Morning Overview on MSN
New “intrabodies” could lead to treatments for MND and Alzheimer’s
Researchers are engineering a new class of miniature antibodies, called intrabodies, that can operate inside living cells to ...
Cells rely on tiny molecules called microRNAs to tune which genes are active and when. Cells must carefully control the lifespan of microRNAs to prevent widespread disruption to gene regulation. A new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results